We aim to develop ATP (energy) enhancing drugs to treat both rare diseases and common diseases caused by energy shortage. Among three important categories for life, i.e. things (molecules), information (genes) and energy (ATP), the last category (energy) has been ignored in medicine. Based on the vast knowledge of the associations between genes and diseases, Naoyuki Kamatani found that mitochondrial disease and neurodegenerative diseases including Parkinson’s disease are caused by energy shortage. Our combination drug, ATP enhancer was developed also based on the knowledge between genes and diseases. We believe that our drug will revolutionize the strategies to treat diseases in medicine.